Frequency Therapeutics, a Phase 2 biotech developing therapies for degenerative diseases, announced terms for its IPO on Monday.
The Woburn, MA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Frequency Therapeutics would command a fully diluted market value of $526 million.
Frequency Therapeutics was founded in 2014 and plans to list on the Nasdaq under the symbol FREQ. J.P. Morgan, Goldman Sachs, and Cowen are the joint bookrunners on the deal. It is expected to price during the week of September 30, 2019.
The article Degenerative disease biotech Frequency Therapeutics sets terms for $101 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
